Real-world evidence has been generating a stir in the world of drug development — and now, some of its boosters believe it may even have a role to play in the fight against Covid-19.
An increasingly pervasive buzzword, real-world evidence is fueled by data that gets collected outside of the controlled setting of a clinical trial to assess the safety and effectiveness of a medication. That could be data from records of insurance payouts, electronic health record systems, a patient registry, a wearable device, or social media.
One of the best-known executives in the space is Carolyn Magill, the CEO of Aetion, a New York City-based health tech company that specializes in real-world evidence. Aetion sells software to biopharma companies and other customers to help them analyze these data. In a recent interview with STAT, she talked about the promise and limitations of her field.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
